BIOMAT Database Logo BIOMAT Database Logo

High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. 1998

L A Holmberg, and T Demirer, and S Rowley, and C D Buckner, and G Goodman, and R Maziarz, and J Klarnet, and N Zuckerman, and G Harrer, and R McCloskey, and R Gersh, and R Goldberg, and W Nichols, and A Jacobs, and P Weiden, and P Montgomery, and S Rivkin, and F R Appelbaum, and W I Bensinger
Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Puget Sound Oncology Consortium, Seattle 98109-1024, USA.

The purpose of this study was to evaluate the efficacy of high-dose chemotherapy (HDC) with busulfan, melphalan and thiotepa (BUMELTT) followed by autologous PBSC infusion in treating patients with advanced ovarian cancer. Thirty-one patients, 18 with stage III/IIIc and 13 with stage IV ovarian cancer, were treated with BU (12 mg/kg), MEL (100 mg/m2) and TT (500 mg/m2) and autologous PBSC rescue. Fifteen patients were in clinical complete remission (CR) at treatment; 11 had platinum-sensitive disease. Sixteen patients were not in CR; two had platinum-sensitive disease. The probabilities of overall survival (OS), event-free survival (EFS) and relapse (R) for all patients at 18 months were 0.57, 0.30 and 0.63; for patients in CR, the rates were 0.87, 0.44 and 0.49 and for patients not in CR, 0.38, 0.13 and 0.81. Two patients (6.5%) died of treatment-related causes. Among the 13 patients with platinum-sensitive disease, all are still alive, with seven having relapsed 129-1021 days after PBSC infusion. OS, EFS and R were 1.00, 0.52 and 0.48. Of the 18 patients with platinum-resistant disease, four remain alive (two in remission). Six patients did not respond and eight relapsed from days 104-429. The OS, EFS and R were 0.33, 0.11 and 0.78. We conclude that BUMELTT is well tolerated in patients with advanced ovarian cancer and results are equivalent to other published HDC regimens.

UI MeSH Term Description Entries
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002066 Busulfan An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D013852 Thiotepa A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed). Thio-Tepa,Thiophosphamide,Triethylenethiophosphoramide,AI3-24916,Girostan,NSC-6396,Tespa,Tespamin,Tris(1-aziridinyl)phosphine Sulfide,AI3 24916,AI324916,NSC 6396,NSC6396,Thio Tepa

Related Publications

L A Holmberg, and T Demirer, and S Rowley, and C D Buckner, and G Goodman, and R Maziarz, and J Klarnet, and N Zuckerman, and G Harrer, and R McCloskey, and R Gersh, and R Goldberg, and W Nichols, and A Jacobs, and P Weiden, and P Montgomery, and S Rivkin, and F R Appelbaum, and W I Bensinger
High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
November 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
L A Holmberg, and T Demirer, and S Rowley, and C D Buckner, and G Goodman, and R Maziarz, and J Klarnet, and N Zuckerman, and G Harrer, and R McCloskey, and R Gersh, and R Goldberg, and W Nichols, and A Jacobs, and P Weiden, and P Montgomery, and S Rivkin, and F R Appelbaum, and W I Bensinger
High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
November 2004, Bone marrow transplantation,
L A Holmberg, and T Demirer, and S Rowley, and C D Buckner, and G Goodman, and R Maziarz, and J Klarnet, and N Zuckerman, and G Harrer, and R McCloskey, and R Gersh, and R Goldberg, and W Nichols, and A Jacobs, and P Weiden, and P Montgomery, and S Rivkin, and F R Appelbaum, and W I Bensinger
High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
May 2003, Bone marrow transplantation,
L A Holmberg, and T Demirer, and S Rowley, and C D Buckner, and G Goodman, and R Maziarz, and J Klarnet, and N Zuckerman, and G Harrer, and R McCloskey, and R Gersh, and R Goldberg, and W Nichols, and A Jacobs, and P Weiden, and P Montgomery, and S Rivkin, and F R Appelbaum, and W I Bensinger
High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer.
June 1997, Bone marrow transplantation,
L A Holmberg, and T Demirer, and S Rowley, and C D Buckner, and G Goodman, and R Maziarz, and J Klarnet, and N Zuckerman, and G Harrer, and R McCloskey, and R Gersh, and R Goldberg, and W Nichols, and A Jacobs, and P Weiden, and P Montgomery, and S Rivkin, and F R Appelbaum, and W I Bensinger
Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.
February 2016, Bone marrow transplantation,
L A Holmberg, and T Demirer, and S Rowley, and C D Buckner, and G Goodman, and R Maziarz, and J Klarnet, and N Zuckerman, and G Harrer, and R McCloskey, and R Gersh, and R Goldberg, and W Nichols, and A Jacobs, and P Weiden, and P Montgomery, and S Rivkin, and F R Appelbaum, and W I Bensinger
Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
November 1994, Bone marrow transplantation,
L A Holmberg, and T Demirer, and S Rowley, and C D Buckner, and G Goodman, and R Maziarz, and J Klarnet, and N Zuckerman, and G Harrer, and R McCloskey, and R Gersh, and R Goldberg, and W Nichols, and A Jacobs, and P Weiden, and P Montgomery, and S Rivkin, and F R Appelbaum, and W I Bensinger
Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation.
November 2020, International journal of hematology,
L A Holmberg, and T Demirer, and S Rowley, and C D Buckner, and G Goodman, and R Maziarz, and J Klarnet, and N Zuckerman, and G Harrer, and R McCloskey, and R Gersh, and R Goldberg, and W Nichols, and A Jacobs, and P Weiden, and P Montgomery, and S Rivkin, and F R Appelbaum, and W I Bensinger
131 I-Meta-iodobenzylguanidine followed by busulfan and melphalan and autologous stem cell rescue in high-risk neuroblastoma.
February 2021, Pediatric blood & cancer,
L A Holmberg, and T Demirer, and S Rowley, and C D Buckner, and G Goodman, and R Maziarz, and J Klarnet, and N Zuckerman, and G Harrer, and R McCloskey, and R Gersh, and R Goldberg, and W Nichols, and A Jacobs, and P Weiden, and P Montgomery, and S Rivkin, and F R Appelbaum, and W I Bensinger
Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
November 2020, Pediatric transplantation,
L A Holmberg, and T Demirer, and S Rowley, and C D Buckner, and G Goodman, and R Maziarz, and J Klarnet, and N Zuckerman, and G Harrer, and R McCloskey, and R Gersh, and R Goldberg, and W Nichols, and A Jacobs, and P Weiden, and P Montgomery, and S Rivkin, and F R Appelbaum, and W I Bensinger
Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen.
May 2004, Bone marrow transplantation,
Copied contents to your clipboard!